Needham & Company LLC set a $104.00 price target on Neurocrine Biosciences (NASDAQ:NBIX) in a report published on Wednesday. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. Oppenheimer set a $140.00 price target on shares of Neurocrine Biosciences and gave the company a buy rating in a report on Tuesday, December 11th. Cantor Fitzgerald set a $150.00 price target on shares of Neurocrine Biosciences and gave the company a buy rating in a report on Wednesday, December 5th. Canaccord Genuity began coverage on shares of Neurocrine Biosciences in a report on Wednesday, November 21st. They issued a buy rating and a $111.00 price target for the company. BidaskClub lowered shares of Neurocrine Biosciences from a hold rating to a sell rating in a research note on Friday, November 16th. Finally, ValuEngine lowered shares of Neurocrine Biosciences from a strong-buy rating to a buy rating in a research note on Thursday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seventeen have assigned a buy rating to the stock. The stock has an average rating of Buy and an average price target of $104.62.

Shares of NASDAQ NBIX opened at $71.34 on Wednesday. Neurocrine Biosciences has a twelve month low of $64.72 and a twelve month high of $126.98. The stock has a market capitalization of $6.47 billion, a price-to-earnings ratio of 1,426.80, a price-to-earnings-growth ratio of 17.88 and a beta of 0.90.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Monday, November 5th. The company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.04. Neurocrine Biosciences had a net margin of 2.40% and a return on equity of 2.54%. The company had revenue of $151.80 million during the quarter, compared to the consensus estimate of $151.51 million. During the same period in the prior year, the company earned ($0.13) EPS. Neurocrine Biosciences’s revenue was up 149.7% on a year-over-year basis. Equities research analysts anticipate that Neurocrine Biosciences will post 0.18 earnings per share for the current fiscal year.

In other news, insider Malcolm Lloyd-Smith sold 9,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $110.01, for a total value of $990,090.00. Following the transaction, the insider now owns 21,018 shares in the company, valued at approximately $2,312,190.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gary A. Lyons sold 15,000 shares of the company’s stock in a transaction dated Friday, November 2nd. The shares were sold at an average price of $114.41, for a total value of $1,716,150.00. The disclosure for this sale can be found here. Insiders have sold 38,925 shares of company stock valued at $4,204,191 over the last ninety days. Insiders own 4.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC increased its holdings in shares of Neurocrine Biosciences by 0.5% in the 2nd quarter. FMR LLC now owns 13,451,201 shares of the company’s stock valued at $1,321,446,000 after purchasing an additional 60,325 shares during the period. Vanguard Group Inc increased its holdings in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Vanguard Group Inc now owns 7,772,236 shares of the company’s stock valued at $955,597,000 after purchasing an additional 204,065 shares during the period. Perceptive Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 1.3% in the 3rd quarter. Perceptive Advisors LLC now owns 4,777,254 shares of the company’s stock valued at $587,363,000 after purchasing an additional 62,004 shares during the period. First Trust Advisors LP increased its holdings in shares of Neurocrine Biosciences by 4.2% in the 3rd quarter. First Trust Advisors LP now owns 1,020,857 shares of the company’s stock valued at $125,514,000 after purchasing an additional 41,186 shares during the period. Finally, OppenheimerFunds Inc. increased its holdings in shares of Neurocrine Biosciences by 2.0% in the 2nd quarter. OppenheimerFunds Inc. now owns 851,453 shares of the company’s stock valued at $83,647,000 after purchasing an additional 16,455 shares during the period. Institutional investors own 96.96% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Featured Story: Technical Analysis of Stocks and What It Means

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.